Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Deals
|
M&A
|
Financials
|
Strategy
|
Lifecycle Management
|
Legal
|
Business
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
Index appoints Johnson partner
02 September 2010
Index Ventures, the global high tech venture capitalist, has appointed Dr Kevin Johnson as a life sciences partner to enhance its push into developing asset-centric investment strategy. Dr Johnson, who was both a venture adviser and CEO of PanGenetics, an Index portfolio company whose lead anti-NGF antibody asset was sold to Abbott Laboratories last November, will focus specifically on looking for opportunities in the biologics area. "Biologics is my comfort zone so I will be mostly looking ...
 
Pfizer to bolster rare disease portfolio with FoldRx acquisition
02 September 2010
Pfizer has reiterated its commitment to developing an orphan and rare diseases franchise by acquiring the private US company FoldRx Pharmaceuticals. The two companies did not disclose the financial terms of the acquisition, though Pfizer will make an upfront payment and further payments depending ...
Deal with Ono the first for Concordia's novel Ras inhibitor
02 September 2010
Ono Pharmaceutical has acquired exclusive development and commercialisation rights in Japan to Concordia Pharmaceuticals' direct Ras inhibitor salirasib, which it will develop initially for pancreatic cancer. The Japanese firm will pay undisclosed upfront and milestone payments to privately held ...
 
Genzyme snubs offer from Sanofi-Aventis
31 August 2010
After months of speculation Sanofi-Aventis, the French pharma major, at the weekend unveiled an all-cash $69.00 a share bid for Genzyme, which values the US biotech at about $18.5 billion. Not surprisingly, the Genzyme board unanimously rejected the offer claiming it to be "an opportunistic ...
Novartis becomes majority owner of Alcon
26 August 2010
Novartis has completed its acquisition of a 52% stake in the eyecare firm Alcon from Nestlé. The Swiss pharma giant paid $28.3 billion for the stake, taking its total share of Alcon up to 77%. It had bought a 25% stake in the company from Nestlé for $10.4 billion in July 2008. Novartis's majority ...
 
Pfizer to bolster rare disease portfolio with FoldRx acquisition
02 September 2010
Pfizer has reiterated its commitment to developing an orphan and rare diseases franchise by acquiring the private US company FoldRx Pharmaceuticals. The two companies did not disclose the financial terms of the acquisition, though Pfizer will make an upfront payment and further payments depending ...
Relief for Dendreon on upcoming US Medicare coverage meeting on Provenge
02 September 2010
The US agency that runs Medicare – the Centers for Medicare and Medicaid Services (CMS) - has scheduled a 17 November advisory panel meeting to consider on-label and off-label use of Dendreon's prostate cancer treatment Provenge (sipuleucel-T). Provenge is a first-of-its kind approach, approved by ...
 
Index appoints Johnson partner
02 September 2010
Index Ventures, the global high tech venture capitalist, has appointed Dr Kevin Johnson as a life sciences partner to enhance its push into developing asset-centric investment strategy. Dr Johnson, who was both a venture adviser and CEO of PanGenetics, an Index portfolio company whose lead ...
Ranbaxy opens second plant in South Africa
01 September 2010
Ranbaxy Laboratories has opened its second manufacturing facility in South Africa at Roodepoort, Johannesburg, at an investment of $30 million. It will manufacture a range of products including analgesics, cold, cough and flu preparations, antihistamines, antihypertensives and CNS medicines, ...
 
Extended review for Acetadote supplement hits Cumberland shares
25 August 2010
Shares in Cumberland Pharmaceuticals, which have languished since the company broke the deadlock in a recession-hit pharmaceutical sector by raising around $75 million net in an IPO last August, took a further battering yesterday after Cumberland announced a delay in the FDA's review of a new ...
FDA panels vote against Jazz bid to sell sodium oxybate for fibromyalgia
23 August 2010
A joint meeting on 20 August of two US FDA advisory committees put major roadblocks in the way of Jazz Pharmaceuticals' new drug application (NDA) to sell sodium oxybate as a treatment for fibromyalgia. The panel of outside experts on arthritis products and drug safety and risk management, who were ...
 
US judge denies Sanofi-Aventis's bid to stop generic rival for Lovenox
31 August 2010
A federal judge has denied Sanofi-Aventis 's request for a preliminary injunction that would have directed the US FDA to suspend and withdraw its approval of a generic version of Lovenox (enoxaparin sodium) from Sandoz (Novartis) and partner Momenta Pharmaceuticals, which has been on the market for ...
Olainfarm wins brand dispute with Grindeks
25 August 2010
A district court in Riga, Latvia, has withdrawn a temporary injunction for Olainfarm 's cardiovascular product containing generic meldonium, which had been imposed on 28 July. The verdict was final with no right to appeal. Meldonium is the active pharmaceutical ingredient for Mildronate, the ...
 

Calling German and Spanish Physicists: the EMA Needs You
13 July 2010
Maureen Kenny
German or Spanish physicists hoping for a career change involving a move to London at the end of ...

© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm